Cytek Biosciences Inc (CTKB)vsStryker Corporation (SYK)
CTKB
Cytek Biosciences Inc
$4.09
-5.54%
HEALTHCARE · Cap: $559.19M
SYK
Stryker Corporation
$305.66
+2.15%
HEALTHCARE · Cap: $112.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 12277% more annual revenue ($25.27B vs $204.17M). SYK leads profitability with a 13.2% profit margin vs -36.2%. SYK earns a higher WallStSmart Score of 59/100 (C).
CTKB
Hold41
out of 100
Grade: D
SYK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+42.8%
Fair Value
$7.62
Current Price
$4.09
$3.53 discount
Margin of Safety
-35.2%
Fair Value
$223.02
Current Price
$305.66
$82.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Areas to Watch
Smaller company, higher risk/reward
ROE of -22.6% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.19 — expect wider price swings.
CTKB is growing revenue faster at 6.5% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Bottom Line
SYK scores higher overall (59/100 vs 41/100). CTKB offers better value entry with a 42.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is at the forefront of multi-parameter flow cytometry, offering advanced cell analysis solutions that drive innovation in the life sciences industry. The company's proprietary technologies play a critical role in pivotal research fields such as immunology, cancer diagnostics, and drug development, addressing the growing demand for high-precision cellular analysis. Cytek’s dedication to innovation, coupled with its robust customer support, positions it as a significant player within the biotechnology sector. With a comprehensive product range and a solid market footprint, Cytek is well-equipped to facilitate groundbreaking discoveries that can dramatically enhance healthcare outcomes.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?